$12.94
1.01% yesterday
Nasdaq, Nov 14, 10:00 pm CET
ISIN
US6412881053
Symbol
NPCE

NeuroPace Inc Stock price

$12.94
+2.12 19.59% 1M
-2.66 17.05% 6M
+1.75 15.64% YTD
+3.26 33.68% 1Y
+10.96 553.54% 3Y
-4.06 23.88% 5Y
-4.06 23.88% 10Y
-4.06 23.88% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+0.13 1.01%

Key metrics

Basic
Market capitalization
$426.7m
Enterprise Value
$425.4m
Net debt
positive
Cash
$60.0m
Shares outstanding
33.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.5 | 4.4
EV/Sales
4.5 | 4.4
EV/FCF
negative
P/B
23.0
Financial Health
Equity Ratio
8.5%
Return on Equity
-338.7%
ROCE
-21.4%
ROIC
-
Debt/Equity
3.2
Financials (TTM | estimate)
Revenue
$94.9m | $97.6m
EBITDA
$-18.1m | $-15.9m
EBIT
$-18.7m | $-22.5m
Net Income
$-24.0m | $-28.9m
Free Cash Flow
$-16.6m
Growth (TTM | estimate)
Revenue
24.1% | 22.1%
EBITDA
16.5% | 26.0%
EBIT
18.8% | -3.9%
Net Income
14.6% | -6.6%
Free Cash Flow
1.3%
Margin (TTM | estimate)
Gross
76.8%
EBITDA
-19.1% | -16.3%
EBIT
-19.7%
Net
-25.3% | -29.7%
Free Cash Flow
-17.5%
More
EPS
$-0.7
FCF per Share
$-0.5
Short interest
4.8%
Employees
209
Rev per Employee
$380.0k
Show more

Is NeuroPace Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,041 stocks worldwide.

NeuroPace Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a NeuroPace Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a NeuroPace Inc forecast:

Buy
93%
Hold
7%

Financial data from NeuroPace Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
95 95
24% 24%
100%
- Direct Costs 22 22
10% 10%
23%
73 73
29% 29%
77%
- Selling and Administrative Expenses 64 64
13% 13%
68%
- Research and Development Expense 27 27
17% 17%
28%
-18 -18
17% 17%
-19%
- Depreciation and Amortization 0.61 0.61
55% 55%
1%
EBIT (Operating Income) EBIT -19 -19
19% 19%
-20%
Net Profit -24 -24
15% 15%
-25%

In millions USD.

Don't miss a Thing! We will send you all news about NeuroPace Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroPace Inc Stock News

Neutral
Seeking Alpha
10 days ago
NeuroPace, Inc. ( NPCE ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Scott Scaper Joel Becker - CEO, President & Director Patrick Williams - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Chase & Co, Research Division Priya Sachdeva - UBS Investment Bank, Research Division Michael Kratky - Leerink Partners LLC, Research Division Frank Tak...
Neutral
Business Wire
10 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. Third Quarter 2025 Financial Highlights Total revenue of $27.4 million, representing growth of 30% compared to the third...
Neutral
Business Wire
24 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time ...
More NeuroPace Inc News

Company Profile

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Head office United States
CEO Joel Becker
Employees 209
Founded 1997
Website www.neuropace.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today